1. Introduction {#s0005}
===============

Insulin resistance (INS-R) is broadly defined as the reduced biological action of insulin at its target tissues. INS-R results in chronic hyperglycemia and dyslipidemia characterised by high levels of total cholesterol and triglycerides, and low levels of high-density lipoprotein (HDL) ([@bb0205]). INS-R and dyslipidemia are also major components of the metabolic syndrome ([@bb0005]; [@bb0010]; [@bb0020]; [@bb0145]). INS-R and the associated dyslipidemia are major risk factors for cardiovascular disease and for cardiovascular adversity in type 2 diabetes (T2D) and obesity ([@bb0010]). In addition, insulin has significant functions within the brain ([@bb0125]) where it is involved in biological pathways relevant to neuronal survival ([@bb0265]; [@bb0400]), dendritic outgrowth ([@bb0065]; [@bb0135]), synaptic plasticity ([@bb0365]; [@bb0430]) and cognition, particularly learning and memory ([@bb0105]; [@bb0445]).

Accumulating evidence from observational studies suggests that INS-R, and the associated dyslipidemia, influence cognition and psychopathology. Studies of patients have shown that T2D is associated with significant cognitive dysfunction and increased risk of vascular dementia and Alzheimer\'s disease ([@bb0040]; [@bb0080]; [@bb0085]; [@bb0200]; [@bb0290]; [@bb0295]; [@bb0305]; [@bb0340]; [@bb0345]). Studies of general population cohorts have found that lower general cognitive ability at age 11 years is associated with higher risk of developing T2D in middle adulthood while higher polygenic risk scores for T2D are inversely associated with educational attainment ([@bb0150]; [@bb0270]). In older adults, the associations between cognitive task underperformance and age-related cognitive decline appear to be weak for the polygenic risk for T2D alone ([@bb0220]) and INS-R traits ([@bb0195]; [@bb0465]) but become more pronounced when both INS-R and dyslipidemia are present ([@bb0460]). Collectively, these studies link abnormalities in glycaemic control to dysfunction in global intellectual function and in specific cognitive domains reflecting verbal fluency, processing speed, memory and cognitive flexibility ([@bb0025]; [@bb0115]; [@bb0295]).

A parallel line of research has examined the relationship between INS-R and psychopathology. Meta-analyses indicate that depression increases the risk for the subsequent development of INS-R ([@bb0300]; [@bb0310]) and T2D ([@bb0180]; [@bb0260]). INS-R alone is a rather modest predictor of depressive symptoms or major depressive disorder (MDD) ([@bb0175]) but the association with depression becomes more robust, both cross-sectionally and longitudinally, when significant dyslipidaemia is also present ([@bb0235]; [@bb0415]; [@bb0420]; [@bb0425]).

The relationships between INS-R, cognition and depression are likely to involve diverse and currently poorly understood biological mechanisms. For example, previous literature implicates low grade inflammation ([@bb0210]) as well as activation of the hypothalamic--pituitary--adrenocortical (HPA) axis and of the sympathetic nervous system ([@bb0075]; [@bb0435]). Lifestyle choices and health maintenance decisions are also likely to play a significant role. Both depression and INS-R have been linked to higher caloric intake and obesity ([@bb0140]; [@bb0230]; [@bb0315]) and to low rates of exercise ([@bb0130]; [@bb0185]; [@bb0405]). Antidepressant medications, which are the standard pharmacological treatment for depression, are also known to induce weight gain and metabolic dysregulation ([@bb0160]; [@bb0355]). Disambiguating the contribution of INS-R to depression and cognition in the context of this complex background remains a major challenge.

We sought to advance our understanding of the causality of INS-R for depression and cognition by capitalizing on the lifetime stability of genetic biomarkers and their unidirectional relationship with clinical and cognitive phenotypes. To maximize statistical power and generalizability, we used measures of depression and cognition from two large genotyped population samples, the Generation Scotland: Scottish Family Health Study (GS:SFHS; *N* = 19,994) and the UK Biobank (*N* = 331,374). This allowed us to employ polygenic profile scoring ([@bb0320]) and inverse-variance weighted (IVW) Mendelian Randomization (MR) ([@bb0045]; [@bb0095]; [@bb0370]) to test genetic associations between INS-R related traits, depression and cognition. We found that the polygenic risk score (PRS) for fasting insulin was associated with verbal intelligence and depression while the PRS for homeostasis model assessment of insulin resistance (HOMA-IR) was associated only with verbal intelligence. However, the MR analyses did not provide evidence for causal associations from INS-R traits to either cognition or depression. It is possible that methodological issues such as weak genetic instruments, limited cognitive measures and insufficient power may have contributed to these results. Conversely, the associations of INS-R to depression and cognition may not be causal despite some degree of genetic overlap. This study therefore points to the need to extend the scope of research in this field to examine the mediating roles of other biological mechanisms.

2. Materials and methods {#s0010}
========================

2.1. Cohorts {#s0015}
------------

Genetic, clinical, and cognitive data were extracted from two large-scale population-based cohorts: the Generation Scotland: The Scottish Family Health Study (GS:SFHS) and the UK Biobank.

### 2.1.1. Generation Scotland: the Scottish Family Health Study (GS:SFHS) {#s0020}

The GS:SFHS ([www.generationscotland.co.uk](http://www.generationscotland.co.uk){#ir0005}) is a family- and population-based study consisting of 23,690 participants recruited through 125 general medical practices across Scotland ([@bb0375]; [@bb0380]). Genome-wide genotyping data, depression status and measures of logical memory, digit symbol coding, verbal fluency, and verbal intelligence were available for 19,994 individuals (11,773 females) aged 18--99 years (mean age = 47.41 years, SD = 14.98) ([@bb0150]; [@bb0240]; [@bb0380]; [@bb0470]). A broad definition of depression was based on participants\' responses to a single question as to whether they had ever been affected with depression ([@bb0470]). The prevalence of self-reported lifetime depression in this sample was 10%. Cognition was assessed using the logical memory and digit symbol coding subtests of the Wechsler Memory Scale III ([@bb0440]), the Controlled Oral Word Association Test (COWAT) ([@bb0030]) and the Mill Hill vocabulary test for senior and junior synonyms combined ([@bb0330]), a test designed to measure verbal intelligence. The quality control processes relating to the genetic, clinical and cognitive data have been described in full elsewhere ([@bb0380]; [@bb0470]). Ethical approval for GS:SFHS was granted by the Tayside Research Ethics Committee (reference 05/S1401/89). All participants provided written informed consent.

### 2.1.2. UK Biobank {#s0025}

The UK Biobank ([www.ukbiobank.ac.uk](http://www.ukbiobank.ac.uk){#ir0010}) is a population-based cohort that has detailed health information and biological measures for 501,726 individuals recruited from across the UK ([@bb0060]). The genetic and phenotypic data used in the current study were available for 331,374 unrelated individuals (177,775 females) aged 39--73 years (mean age = 57.2 years, SD = 8.1). Individuals with probable Major Depressive Disorder (MDD) were self-identified based on responses to questions about current and lifetime symptoms and diagnosis of depression ([@bb0165]). The prevalence of this depression phenotype was 17.4%. Cognitive function was measured using the symbol digit substitution score (UK Biobank Field ID 20159), reaction time (UK Biobank Field ID 20023), numeric memory score (UK Biobank Field ID 20240), and trail making test (mean of UK Biobank Fields 20,156 and 20,157). Detailed information regarding the depression and cognitive variables available within UK Biobank has been published previously ([@bb0150]; [@bb0165]). The quality control processes relating to the data analysed here have also been described in detail elsewhere ([@bb0165]; [@bb0225]). The UK Biobank study was approved by the National Health Service Research Ethics Service (approval letter dated 17th June 2011, reference: 11/NW/0382). The analyses presented here were conducted under UK Biobank application 4844.

2.2. Insulin-resistance related traits {#s0030}
--------------------------------------

The euglycemic insulin clamp ([@bb0250]) and the glucose tolerance tests ([@bb0035]) are considered the gold standard methods for the measurement of INS-R in research, but their use is cumbersome in clinical practice and infeasible in large, population-based research studies. Here we consider three reliable surrogate measures: fasting insulin ([@bb0190]), fasting glucose and the homeostasis model assessment of insulin resistance (HOMA-IR) ([@bb0255]), which is based on the dynamic relationship between fasting glucose and corresponding insulin levels. We considered four further traits, HDL cholesterol, Low-density lipoprotein (LDL) cholesterol, triglycerides and total cholesterol, which are components of dyslipidaemia associated with INS-R ([@bb0205]). In total, we focus on seven, genetically overlapping traits, three representing changes in glycaemic control and four representing dyslipidaemia ([@bb0050]).

2.3. Computation of polygenic risk scores in the GS:SFHS {#s0035}
--------------------------------------------------------

Pleiotropy reflects the overlap between the genetic architecture of two or more traits ([@bb0385]) and can be assessed using data from single-nucleotide polymorphism (SNP) genotyping. Polygenic profile scoring ([@bb0320]) uses summary data from genome-wide association studies (GWAS) to test whether genetic liability to a particular trait is associated with another phenotype. Here we examined whether genetic liability, expressed as Polygenic Risk Scores (PRS), to the seven INS-R traits described above, is associated with the measures of cognition and depression available in 19,994 individuals from the GS:SFHS. Specifically, polygenic risk scores were based on GWAS results for HOMA-IR ([@bb0110]), fasting glucose ([@bb0110]), fasting insulin ([@bb0110]), HDL cholesterol ([@bb0450]), Low-density lipoprotein (LDL) cholesterol ([@bb0450]), triglycerides ([@bb0450]) and total cholesterol ([@bb0450]). Quality controlled autosomal SNPs in GS:SFHS were entered in PRSice v1.25 ([@bb0120]) to compute the PRS of each trait at five SNP set *P*-value threshold cutoffs of ≤0.01, ≤ 0.05, ≤ 0.1, ≤ 0.5 and ≤ 1 from the corresponding GWAS summary statistics.

2.4. Statistical analyses {#s0040}
-------------------------

### 2.4.1. Polygenic risk score analyses in the GS:SFHS {#s0045}

We implemented mixed linear model analyses in ASReml-R, to test the association between the PRS of the seven INS-R related traits to cognition and depression in the GS:SFHS; age, sex, the first four multi-dimensional scaling components to control population stratification, and each of the PRS in turn were fitted as fixed effects. To control for relatedness in the sample, the pedigree structure was fitted as a random effect by creating the inverse of a relationship matrix using pedigree kinship information. *P*-values for fixed effects fitted in the model were calculated using Wald\'s conditional F-test. After Bonferroni correction for multiple testing, the threshold of significance for the five SNP sets (corresponding to the 5 threshold cut-offs) and the seven INS-R related traits was set at *P* \< 1.4 × 10^−3^ \[0.05/(5 × 7)\].

We note that [@bb0335] have already published a detailed atlas of the associations between multiple PRS with numerous diverse traits in the UK Biobank, including those of interest to this paper.

### 2.4.2. Mendelian randomization in the GS:SFHS and UK Biobank {#s0050}

MR exploits the random assignment of genotypes at birth and their stability throughout the lifetime to overcome limitations relating to residual confounding (measured or unmeasured) and reverse causation ([@bb0045]; [@bb0095]; [@bb0370]). MR analyses use genetic variants to assess causal relationships between exposures (here INS-R related traits) and outcomes (here depression and cognition) ([Fig. 1](#f0005){ref-type="fig"}). MR analyses were conducted separately in the GS:SFHS and UK Biobank. As instrumental variables for INS-R we used the 53 SNPs (Supplementary Table S1) defined by Lotta and colleagues ([@bb0215]). Lotta and colleagues used all SNPs independently-associated with higher fasting insulin adjusted for body mass index \[from up to 108,557 participants of the Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC; <https://www.magicinvestigators.org>)\] and lower HDL cholesterol and higher triglycerides \[from up to 188,577 participants of Global Lipids Genetics Consortium (GLGC; <http://lipidgenetics.org>)\]. For fasting glucose, fasting insulin, triglycerides, HDL, LDL, and total cholesterol we used significant GWAS hits available in the MR-Base GWAS catalogue ([@bb0155]) (detailed in Supplementary Table S2). Depression and cognitive measures, as defined in 2.1, were used as outcome variables. All two-sample MR analyses were performed using the MR-Base R package ("TwoSampleMR") version 0.4.8 (<https://github.com/MRCIEU/TwoSampleMR>) using inverse variance weighted (IVW) method and MR-Egger intercept tests. The IVW method is based on a regression of the exposure and outcome genetic variant vectors with the intercept constrained to zero, as described by Burgess and colleagues ([@bb0055]). In total, 10 two-sample MR tests were performed and the threshold for significance was set at *P* \< 5 × 10^−3^ (0.05/10) following Bonferroni correction for multiple testing.Fig. 1Model for two-sample Mendelian randomization study. Mendelian randomization can be used to test if the exposure (insulin resistance) causally influences the outcome (depression and cognition) by using instrumental genetic variables (genome-wide significant SNPs) associated with the exposure that are unrelated to potential confounders and only affect the outcome via the exposure.Fig. 1

3. Results {#s0055}
==========

3.1. Polygenic risk score analyses in the GS:SFHS {#s0060}
-------------------------------------------------

In the GS:SFHS, at *P* \< 1.4 × 10^−3^, the risk of depression was positively associated with higher PRS for fasting insulin while verbal intelligence (assessed with the Mill Hill Vocabulary test) was associated with the PRS for fasting insulin and for HOMA-IR. At the nominal threshold of statistical significance (*P* \< .05), additional associations were found between depression and the PRS for HOMA-IR. At the same level, the PRS for HOMA-IR was associated with processing speed (assessed with the digit symbol substitution task), while verbal intelligence was associated with the PRS for triglycerides and fasting glucose. The results of all the PRS analyses in the GS:SFHS are described in [Table 1](#t0005){ref-type="table"}.Table 1Polygenic risk score anlysis of the seven INS-R traits on the depression and cognition in GS:SFHS (*N* = 19,994) cohort.Table 1Predicted TraitPolygenic predictorCutoff [⁎](#tf0005){ref-type="table-fn"}Betas.e.*P*-valueVarExpSignificant (*P* \< .0014)Nominally significant (*P* \< .05)DepressionHDL1−0.0103780.0074870.1657141.08E-04NoNoDepressionLDL0.50.0113190.0076250.1377231.28E-04NoNoDepressionTotal cholesterol0.50.0059020.0075220.432663.48E-05NoNoDepressionTriglycerides10.011180.0077930.1514081.25E-04NoNoDepressionFasting glucose0.5−0.0095540.0075070.2031429.13E-05NoNo**DepressionFasting insulin10.0246520.007520.0010456.08E-04YesYes**DepressionHOMA-IR10.0187650.0075370.0127833.52E-04NoYesDigit symbol codingHDL0.010.0098520.006440.1260379.71E-05NoNoDigit symbol codingLDL0.5−0.0073720.0065940.2636135.43E-05NoNoDigit symbol codingTotal cholesterol0.05−0.0028550.0064690.6589768.15E-06NoNoDigit symbol codingTriglycerides1−0.0164960.0067290.0142242.72E-04NoYesDigit symbol codingFasting glucose0.05−0.007820.0064820.2276956.11E-05NoNoDigit symbol codingFasting insulin1−0.0186560.0064910.004053.48E-04NoYesDigit symbol codingHOMA-IR1−0.0189270.0065010.0035973.58E-04NoYesLogical memoryHDL10.0066230.0072680.362174.39E-05NoNoLogical memoryLDL1−0.0053360.0074070.4712472.85E-05NoNoLogical memoryTotal cholesterol0.10.0028370.0072950.6973548.05E-06NoNoLogical memoryTriglycerides0.050.0064010.0076770.4043984.10E-05NoNoLogical memoryFasting glucose10.0057220.0072850.4321813.27E-05NoNoLogical memoryFasting insulin0.10.0070120.0073050.3370744.92E-05NoNoLogical memoryHOMA-IR0.05−0.0044020.0073120.5471661.94E-05NoNoVerbal fluencyHDL0.010.0123770.0074940.0986211.53E-04NoNoVerbal fluencyLDL0.010.0117430.0075440.1195581.38E-04NoNoVerbal fluencyTotal cholesterol0.010.016960.0074990.0237142.88E-04NoYesVerbal fluencyTriglycerides0.5−0.0079070.0078460.3135746.25E-05NoNoVerbal fluencyFasting glucose0.10.0080790.0075420.284066.53E-05NoNoVerbal fluencyFasting insulin0.5−0.0124080.0075490.1002341.54E-04NoNoVerbal fluencyHOMA-IR0.01−0.0092190.0075420.2215468.50E-05NoNoVerbal intelligenceHDL0.050.0069180.0070940.3294514.79E-05NoNoVerbal intelligenceLDL0.010.0059260.0071390.4064713.51E-05NoNoVerbal intelligenceTotal cholesterol0.10.013630.0071350.0560781.86E-04NoNoVerbal intelligenceTriglycerides0.010.0189140.0074790.0114443.58E-04NoYesVerbal intelligenceFasting glucose0.1−0.0164260.0071260.0211542.70E-04NoYes**Verbal intelligenceFasting insulin0.5−0.0274820.007130.0001167.55E-04YesYesVerbal intelligenceHOMA-IR1−0.025210.0071430.0004166.36E-04YesYes**[^2][^3]

According to [@bb0335]; [http://mrcieu.mrsoftware.org/PRS_atlas/](http://mrcieu.mrsoftware.org/PRS_atlas){#ir1030}), in the UK Biobank depression and intelligence were associated with all the INS-R polygenic risk scores; these results can be accessed at <http://mrcieu.mrsoftware.org/PRS_atlas>

3.2. Mendelian randomization in the GS:SFHS and UK Biobank {#s0065}
----------------------------------------------------------

The MR analyses provided no evidence of any significant (*P* \< 5 × 10^−3^) causal associations from any INS-R related trait to cognition and depression in either GS:SFHS or UK Biobank (Supplementary Tables S3--S9).

4. Discussion {#s0070}
=============

We sought to identify causal relationships between INS-R related traits, cognition and depression in two large population-based cohorts using polygenic profiling and Mendelian Randomization. The polygenic profiling indicated a degree of overlap in the genetic architecture of fasting insulin and HOMA-IR with depression and verbal intelligence. The MR analyses however showed no evidence of significant causal relationships from INS-R related traits to depression and cognition.

Our results support observational studies in general population samples reporting phenotypic associations between INS-R traits, cognition ([@bb0195]; [@bb0220]; [@bb0460]; [@bb0465]) and depression ([@bb0175]; [@bb0300]; [@bb0310]). The polygenic risk score analyses in the GS:SFHS and results available from similar analyses in the UK Biobank ([@bb0335]) show reproducibility for the association between the PRS for fasting insulin and HOMA-IR with global measures of intelligence and with the risk of depression. These findings suggest a degree of genetic overlap between INS-R traits with depression and cognition. However, the PRS approach is liable to yield substantive false positive rates due to horizontal pleiotropy, the phenomenon whereby a gene (or genes) influences multiple traits ([@bb0095]). These pleiotropic effects are very common and PRS scores for one trait seem to be associated with multiple other traits ([@bb0335]).

Mendelian randomization (MR) enables further interrogation of these genetic associations to identify causal pathways between genetic risk factors and complex human traits ([@bb0045]; [@bb0095]; [@bb0370]). In simple terms, MR examines the effect of INS-R on depression risk (or another trait) by comparing the rates of depression in individuals with and without genotypes that predispose to INS-R. As any particular genotype is randomly assigned at birth and is not subject to reverse causation, the use of genetic variants (such as SNPs) provides a way of "randomising" a sample so that the causality of an observed association can be assessed. Consistent with previous large-scale studies ([@bb0050]; [@bb0150]), we found no evidence of directional associations from INS-R traits to cognition and depression. We therefore infer that these associations are likely to be mediated by other mechanisms, that are either consequent on INS-R or interact with INS-R pathways. In the context of diabetes, chronic hyperglycemia may cause cognitive impairment through direct adverse effects on synaptic plasticity ([@bb0170]) and neurogenesis ([@bb0015]). Hyperinsulinemia and INS-R can induce neuroglial energy deficits ([@bb0475]) and/or interfere with protein kinase C related synaptic plasticity and neuronal repair ([@bb0275]). Further, hyperinsulinemia has been shown to promote amyloid accumulation within the brain by limiting the degradation and clearance of the amyloid-β peptide ([@bb0090]; [@bb0280]). Alternatively, the link between INS-R and cognitive dysfunction and depression may be mediated by inflammatory pathways ([@bb0395]) and/or oxidative stress linked to mitochondrial dysfunction ([@bb0070]). Mitochondria integrate glucose and lipid metabolism; specifically, insulin regulates mitochondrial metabolism and oxidative capacity through PI3K/Akt signalling ([@bb0390]). Finally, cardiovascular pathology in the context of INS-R and diabetes may also play a significant role. For example, in a sample of 2305 individuals aged ≥60 years Marseglia and colleagues found that cognitive dysfunction was present only among participants who had both uncontrolled diabetes and vascular disorders/risk factors ([@bb0245]).

There are several methodological considerations pertinent to interpreting the current findings. A particular strength of this study is the availability of data from two large general population samples in which all participants were assessed using harmonised protocols; this contrasts with most large-scale studies that rely on data pooled across diverse cohorts. The instrumental variables used in the analyses were based on the most up-to-date information from the largest GWAS. The polygenic and MR analyses examine the putative causative role of multiple INS-R related traits; however, each of these traits is highly polygenic and instrumental variables tend to explain a small amount of the variance in cognitive ability and depression. The cognitive measures considered in the GS:SFHS and in the UK Biobank covered the domains of cognitive function that have been consistently implicated in INS-R and T2D in observational studies ([@bb0025]; [@bb0115]; [@bb0295]). However, as the hippocampus is enriched in insulin receptors ([@bb0100]; [@bb0455]) and is sensitive to INS-R and depression ([@bb0360]) our cognitive battery could have benefited from additional tests targeting hippocampus-linked episodic memory ([@bb0410]). A further limitation is that case ascertainment was primarily based on self-report which may have led to inaccuracies in the phenotype due to recall bias.

In summary, this study did not find robust evidence for causal associations between INS-R with depression and cognitive ability. Future work should focus on improving instrumental variables, examining a wider range of depression and cognitive phenotypes and focusing on biological mechanisms that may mediate the central effects of INS-R.

Appendix A. Supplementary data {#s0090}
==============================
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